Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

SC6177

Source date not recordedAnalyse record ↗

Preclinical PLA2G15 inhibitor intended to restore protective lysosomal lipid biology across genetic and age-related neurodegeneration.

Modality
oral brain-penetrant small-molecule PLA2G15 inhibitor
Availability (US)
IND-enabling development; first-in-human trials are targeted for 2027 and have not yet begun
Biomarkers
PLA2G15 inhibition; bis(monoacylglycero)phosphate; lysosomal function and lipid handling
Hallmark targeted
disabled autophagy, loss of proteostasis, intracellular lipid accumulation
Kind
investigational drug